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15-Deoxyspergualin (DSPG) is a new antitumor and immunosuppressive agent derived from
the antibiotic spergualin. This agent was shown to prolong the graft survival of skin, heart,
pancreas islet, kidney, and liver in the rodent. 1–3 No observations have been made with large
animals. In the present study, the effect of DSPG was first tested with rat heterotopic heart
transplantation (HTX) and then evaluated with canine kidney transplantation (KTX).
MATERIALS AND METHODS
Animals
Lewis rats (RT 1) purchased from the Harlan Spraque Dawley Company (Indianapolis) were
used as recipients. ACI rats (RT 1a) were purchased from the Simonsen Lab (Gilcoy, CA) and
used as donors.
Outbred beagle dogs were obtained from the University of Pittsburgh farm and were used as
both donors and recipients.
Operative Procedures
HTX was performed by the method of Ono and Lindsay.4 The donor aorta and pulmonary
artery were anastomosed to the recipient aorta and infrarenal inferior vena cava with standard
microvascular techniques. KTX was performed by conventional intra-abdominal techniques,
with which the renal artery was anastomosed to the recipient iliac artery end-to-end and the
renal vein was anastomosed to the recipient iliac vein end-to-side. Bilateral native nephrectomy
was performed after graft uretero-neocystostomy.
Drug Administration
DSPG was supplied as a powder from the Nippon Kayaku Company, Ltd, Tokyo. It was
dissolved in saline, and was given intraperitoneally to the rat for 2 weeks and intravenously to
the dog for 50 days starting immediately after the transplant operation. In experiments with
drug combinations in dogs, cyclosporine (CyA) was given orally in the commercial oil carrier
that is used clinically. Oral prednisone (Pred) was given to dogs as a 5-mg tablet.
Experimental Groups
Intraperitoneal doses tested in HTX were 0.0 mg/kg/d (control), 0.5 mg/kg/d, 1.0 mg/kg/d, 3.0
mg/kg/d, and 6.0 mg/kg/d. Treatment was for 14 days beginning just after the operation.
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Rejection was diagnosed by the cessation of heartbeat and was confirmed visually by
laparotomy and histologic examination.
The effect of intravenous DSPG alone and in combination with oral CyA and Pred on KTX
were examined in the following groups:
1. Dose-effectiveness study
Group 1: (N = 6) DSPG (0.0 mg/kg/d)
Group 2: (N = 6) DSPG (0.25 mg/kg/d)
Group 3: (N = 6) DSPG (0.5 mg/kg/d)
Group 4: (N = 6) DSPG (0.75 mg/kg/d)
Group 5: (N = 6) DSPG (1.0 mg/kg/d)
2. Combination study
Group 6: (N = 10) DSPG (0.5 mg/kg/d) + CyA (5 mg/kg/d) + Pred (5 mg/d)
Group 7: (N = 6) DSPG (0.5 mg/kg/d) + CyA (5 mg/kg/d)
Group 8: (N = 6) DSPG (0.5 mg/kg/d) + Pred (5 mg/d)
Group 9: (N = 6) CyA (5 mg/kg/d) + Pred (5 mg/d)
Group 10: (N = 6) CyA (5 mg/kg/d)
Group 11: (N = 6) Pred (5 mg/d)
Because of emaciation of animals, the dose of DSPG in the combination experiments was
reduced to 0.3 mg/kg/d after 3 weeks and to 0.2 mg/kg/d after 6 weeks. Blood samples were
collected every three mornings for the determination of kidney and liver functions. Complete
postmortem examination of animals was performed. Histologic severity of graft rejection was
determined blindly basing on subjective scales from 0 to + + +.
Statistics
Wilcoxon rank sum test and Student’s t test were applied for the statistical analysis.
RESULTS
HTX
The median graft survival of untreated rats was six days (Table 1). Intraperitoneal DSPG
administration at doses of 0.5 mg/kg/d and 1.0 mg/kg/d provided significant prolongation of
graft survival. Higher doses were lethal. Four of six rats in group 4 and all animals in group 5
died of bronchopneumonia even though the grafts were beating. Colony contamination with
pathogens could not be shown by serologic and microbiologic study of nontransplanted rats
from the same laboratory environment. Thus, the deaths were attributed to over
immunosuppression.
KTX
Dose-effectiveness study—Mean survival was 13.3 ± 3.6 (SD) days in untreated control
dogs, (Fig 1) while that of treated dogs (groups 2 to 5) was variable. Significant prolongation
of graft survival was obtained only with a dose of 0.75 mg/kg/d, group 4 (Fig 1), even though
higher doses prevented creatinine (Cr) elevation (Fig 2) and even though histologic evidence
of rejection was reduced at higher doses. The last Cr prior to animal death was 15.0 ± 4.6 (SD)
mg/dL in group 1, 11.3 ± 3.8 in group 2, 5.4 ± 1.5 in group 3, 2.7 ± 2.8 in group 4; and 5.1 ±
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3.4 in group 5. The prevention of Cr rise was significant in animals treated with 0.5 mg/kg/d
or more of DSPG compared to groups 1 and 2. All animals given 1.0 mg/kg/d of DSPG died
of lethal emaciation accompanied with severe diarrhea. Liver dysfunction was not observed in
any group. Pulmonary congestion was the only pathologic abnormality in the extrarenal organs
seemingly related to animal death.
Drug combination—The results were compared with those in group 3 in which 0.5 mg/kg/
d DSPG alone prolonged survival from 2 to about 3 weeks. The addition of 5 mg/kg/d CyA
with (group 6) or without prednisone (group 7) augmented this effect, but not beyond what
could be achieved with CyA alone (Group 10) or CyA plus prednisone (group 9) (Fig 3). Thus,
a clean-cut synergistic effect of DSPG with these other agents was not demonstrable.
The best results were with cyclosporine, steroids, and DSPG. Elevation of Cr was well inhibited
in this group of animals even though they died during the treatment. Emaciation and diarrhea
were prominent in animals that were treated with DSPG for more than 3 weeks. Consequently,
the dose of DSPG had to be reduced. Complete histopathologic analyses in animals subjected
to the combination study has not yet been completed, but a preliminary observation is that
rejection was absent or minimal in dogs under triple drug treatment.
DISCUSSION
The present study is the first demonstration that DSPG inhibits the rejection of canine kidney
homografts. However, the immunosuppressive effect of DSPG alone was feeble and the
toxicity was unacceptable. Doses of 0.75 mg/kg/d had a minor therapeutic affect but not enough
to yield long animal survival. Doses higher than this caused the dogs to die of lethal emaciation.
Toxicity was somewhat less in rats. However, in contrast to the observation by others,2,3 most
of our rats given higher doses of DSPG died from bronchopneumonia. No pathogen could be
identified. The findings were different than those of Ochia et al3 who reported universal
survival of WKA rats for more than 80 days, using the much higher dose of 10 mg/kg/d
intramuscularly. Sensitivity of rats to DSPG may differ among strains.
Combination therapy is a potential alternative method with which the toxicity of DSPG could
be avoided if a reduced dose would work synergistically with other agents. These hopes were
not encouraged by actual experiments. Toxicity of DSPG persisted and the principal
immunosuppression was from the CyA, which was an ingredient of the “cocktail.” Thus, our
results suggest that DSPG alone or in combination probably will not be useful for clinical
immunosuppression.
Before pushing ahead with more experiments, it may be wise to learn more of the mechanism
of DSPG. DSPG has been said to inhibit the macrophage/phagocyte system instead of affecting
lymphocytes.2 However, there are no well documented experiments to support this contention.
Until such evidence is available, further attempts to combine DSPG with other agents are apt
to be unrewarding.
SUMMARY
DSPG had a definite but relatively feeble immunosuppressive effect in rats undergoing
heterotopic heart transplantation and in dogs after renal transplantation. The drug was toxic in
both species, although less so in rats. In dogs, synergistic interactions with cyclosporine and
steroids were not evident.
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Fig 1.
Survival of KTX dogs treated with different doses of DSPG.
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Fig 2.
Changes in serum creatinine of KTX dogs treated with different doses of DSPG.
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Fig 3.
Survival of KTX dogs treated with DSPG and other drugs; DSPG (0.5 mg/kg/d), CyA (5 mg/
kg/d), and Pred (5 mg/d).
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